BioNTech SE Sponsored ADR (NASDAQ:BNTX) Sees Significant Decrease in Short Interest

BioNTech SE Sponsored ADR (NASDAQ:BNTX) was the recipient of a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 3,537,489 shares, a drop of 20.7% from the February 26th total of 4,462,537 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 2,504,103 shares, the short-interest ratio is currently 1.4 days.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently modified their holdings of the company. Larson Financial Group LLC increased its holdings in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the last quarter. EFG International AG purchased a new stake in BioNTech during the 4th quarter worth about $29,000. Caitong International Asset Management Co. Ltd boosted its position in shares of BioNTech by 520.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after acquiring an additional 260 shares in the last quarter. Financial Consulate Inc. purchased a new position in shares of BioNTech in the 3rd quarter valued at about $36,000. Finally, Huntington National Bank raised its position in shares of BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after acquiring an additional 380 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on BNTX shares. HC Wainwright decreased their price target on BioNTech from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Morgan Stanley cut their price target on shares of BioNTech from $134.00 to $125.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 10th. Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a research note on Tuesday, March 10th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 target price on shares of BioNTech in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average target price of $133.07.

BioNTech Stock Up 2.2%

BNTX stock opened at $87.12 on Tuesday. The company’s 50 day moving average price is $103.23 and its 200 day moving average price is $101.47. The firm has a market capitalization of $21.90 billion, a price-to-earnings ratio of -16.68 and a beta of 1.51. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.